IGC Pharma, Inc.
Financial highlights
| Metric | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 | FY 03/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3M | $1.3M | $911,000 | $397,000 | $898,000 |
| Cost of revenue | $652,000 | $612,000 | $469,000 | $203,000 | $785,000 |
| Gross profit | $619,000 | $733,000 | $442,000 | $194,000 | $113,000 |
| Selling, general & administrative | $4.4M | $6.8M | $8.6M | $13.3M | $7.9M |
| Research and development | $3.7M | $3.8M | $3.5M | $2.3M | $929,000 |
| Operating income | -$7.4M | -$9.8M | -$11.6M | -$15.4M | -$8.7M |
| Pretax income | -$7.1M | -$13.0M | -$11.5M | -$15.0M | -$8.8M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.1M | -$13.0M | -$11.5M | -$15.0M | -$8.8M |
| Balance Sheet | |||||
| Cash and equivalents | $405,000 | $1.2M | $3.2M | $10.5M | $14.5M |
| Current assets | $2.9M | $3.7M | $6.5M | $15.1M | $23.5M |
| Total assets | $8.7M | $9.9M | $17.2M | $26.8M | $35.9M |
| Current liabilities | $2.3M | $2.3M | $1.9M | $2.4M | $2.4M |
| Total liabilities | $2.4M | $2.6M | $2.3M | $2.9M | $3.1M |
| Stockholders' equity | $6.3M | $7.3M | $14.9M | $23.9M | $32.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.8M | -$5.2M | -$7.0M | -$7.5M | -$10.8M |
| Depreciation and amortization | $618,000 | $637,000 | $657,000 | $651,000 | $478,000 |
| Stock-based compensation | $4.3M | $4.6M | $5.5M | $7.0M | $703,000 |
| Capital expenditure | $112,000 | $138,000 | $310,000 | $236,000 | $1.5M |
| Free cash flow | -$4.9M | -$5.3M | -$7.4M | -$7.7M | -$12.3M |
| Impairments | $152,000 | $3.4M | $0 | $833,000 | $0 |
Shares outstanding 100.1M · Free float 72.7%
Annual filing data through FY ended March 31, 2025; float as of July 12, 2026.